EE20/Drospirenone (YAZ, BAY86-5300)

Phase 3

BAYER (BAYRY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

10 competitors in Acne Vulgaris

GALDYCD5789 (trifarotene)

GALDYAdapalene Lotion Vehicle

Drug Information

Target Indication

Acne Vulgaris

Clinical Trial

NCT00818519

Last updated: 12/18/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts